



DIAGNOSTIC SIGNIFICANCE OF BIOCHEMICAL MARKERS IN WOMEN OF
REPRODUCTIVE AGE WITH VIRAL HEPATITIS

Karimova Fazilat Bahramovna

Urgench State Medical Institute

Email: karimovafazilat96@gmail.com

Abstract: Viral hepatitis remains a major global health problem, posing significant risks for women of reproductive age due to its potential impact on fertility, pregnancy outcomes, and maternal-fetal health. Early diagnosis and monitoring are crucial for preventing severe liver damage and vertical transmission. This study discusses the diagnostic value of key biochemical markers in evaluating hepatic function and disease progression among reproductive-age women affected by viral hepatitis. The paper reviews the pathophysiological basis of viral hepatitis, highlights the role of biomarkers such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, alkaline phosphatase (ALP), and γ -glutamyltransferase (GGT), and emphasizes their clinical utility in early detection, prognosis, and therapeutic management. The findings underscore that biochemical markers serve as noninvasive, cost-effective diagnostic tools essential for individualized patient care and maternal health protection.

Keywords: viral hepatitis, women of reproductive age, biochemical markers, liver enzymes, diagnosis, ALT, AST.

1. Introduction

Viral hepatitis represents a group of infectious diseases characterized by inflammation and necrosis of liver tissue caused by hepatotropic viruses, primarily hepatitis A, B, C, D, and E. Globally, more than 350 million people are estimated to suffer from chronic hepatitis B and C, which account for a significant proportion of liver cirrhosis and hepatocellular carcinoma cases (WHO, 2023).

Among women of reproductive age, viral hepatitis presents unique clinical and epidemiological challenges. Physiological changes in pregnancy, hormonal variations, and immunological modulation can alter disease progression, making accurate diagnosis and monitoring imperative. In particular, chronic hepatitis B and C are associated with adverse reproductive outcomes, including miscarriage, preterm labor, intrahepatic cholestasis of pregnancy, and vertical transmission to the fetus (Kumar & Abbas, 2022).

The diagnosis and management of viral hepatitis rely on a combination of **serological**, **molecular**, and **biochemical** indicators. While serological markers confirm viral presence and immune response, biochemical markers provide insight into the degree of hepatic injury and functional impairment. Understanding the diagnostic significance of these biochemical parameters is essential for timely intervention and minimizing maternal-fetal complications.

2. Pathophysiological Background of Viral Hepatitis



The liver performs vital metabolic, synthetic, and detoxification functions. Viral hepatitis triggers inflammatory responses leading to hepatocyte damage, apoptosis, and fibrosis. The immune-mediated cytolysis of infected hepatocytes results in the release of intracellular enzymes into the bloodstream, serving as measurable indicators of liver injury.

The pathogenesis varies with the type of virus:

- **Hepatitis A and E** cause acute, self-limiting infections, typically transmitted through the fecal-oral route.
- **Hepatitis B, C, and D** often lead to chronic infection through parenteral or perinatal transmission, resulting in progressive fibrosis and cirrhosis.

In women of reproductive age, chronic hepatitis may remain asymptomatic until pregnancy, when metabolic demands increase and hepatic dysfunction becomes clinically evident. Therefore, evaluating biochemical markers provides valuable diagnostic and prognostic information during preconception and antenatal care.

3. Biochemical Markers in the Diagnosis of Viral Hepatitis

Biochemical markers are measurable substances that reflect liver cell integrity, biliary function, and synthetic capacity. Their changes in serum concentration indicate hepatocellular injury or cholestatic processes. The following are the key biochemical parameters used in clinical diagnosis:

3.1. Alanine Aminotransferase (ALT)

ALT is a cytosolic enzyme predominantly found in hepatocytes. It serves as the most specific indicator of hepatocellular damage. In viral hepatitis, ALT levels can rise up to 10–20 times the upper normal limit during acute infection, correlating with the degree of necroinflammation.

In chronic hepatitis, fluctuating or persistently elevated ALT levels signify ongoing liver injury. Elevated ALT during pregnancy in infected women suggests possible hepatic flare or viral reactivation, necessitating close monitoring.

3.2. Aspartate Aminotransferase (AST)

AST is located in both the cytoplasm and mitochondria of hepatocytes, as well as in cardiac and skeletal muscle. While less specific than ALT, the **AST/ALT ratio** provides valuable diagnostic insight. In viral hepatitis, the ratio typically remains below 1. However, a ratio exceeding 1 may indicate advanced fibrosis or cirrhosis.

Elevated AST levels, in conjunction with ALT, confirm hepatocellular damage, while disproportionate increases in AST can signal mitochondrial injury or concurrent extrahepatic involvement.

3.3. Bilirubin



Bilirubin metabolism reflects the liver's excretory and conjugation functions. Increased serum bilirubin—particularly conjugated (direct) bilirubin—suggests impaired hepatocellular secretion or obstruction of bile flow.

In women of reproductive age, hyperbilirubinemia can manifest as jaundice, dark urine, and pruritus. Elevated bilirubin during pregnancy warrants differential diagnosis between viral hepatitis and pregnancy-specific liver disorders such as intrahepatic cholestasis or preeclampsia-related hepatic dysfunction.

3.4. Alkaline Phosphatase (ALP)

ALP is a membrane-bound enzyme present in bile canaliculi, bone, and placenta. Although physiologically elevated during pregnancy, a marked increase—especially when accompanied by raised ALT and AST—indicates cholestatic hepatitis or bile duct obstruction. ALP measurement thus assists in differentiating hepatocellular from cholestatic patterns of liver injury.

3.5. γ -Glutamyltransferase (GGT)

GGT is another cholestatic enzyme that reflects biliary epithelial damage and enzyme induction due to viral or toxic insult. Elevated GGT, together with ALP, reinforces the diagnosis of cholestasis. In reproductive-age women, elevated GGT may also result from hepatotoxic drug use or metabolic disorders, underscoring the need for comprehensive interpretation.

3.6. Serum Albumin and Total Protein

Reduced albumin concentration indicates impaired hepatic synthetic function and correlates with chronicity and disease severity. Prolonged hypoalbuminemia may contribute to edema and poor pregnancy outcomes, emphasizing its prognostic importance in long-term monitoring.

4. Diagnostic Significance and Clinical Interpretation

The combined interpretation of biochemical markers offers a dynamic overview of hepatic status. Key diagnostic patterns include:

Pattern Type	Primary Marker Elevation	Interpretation
Hepatocellular	ALT, AST	Acute viral hepatitis or flare-up
Cholestatic	ALP, GGT, bilirubin	Bile duct obstruction, cholestatic hepatitis
Mixed	ALT, AST, ALP	Chronic or severe hepatitis
Synthetic failure	Low albumin, prolonged prothrombin time	Cirrhosis, hepatic insufficiency

The **temporal monitoring** of biochemical markers aids in evaluating disease progression and treatment response. For instance:



- A decline in ALT and AST after antiviral therapy indicates recovery.
- Persistent elevation despite treatment suggests ongoing viral replication or drug resistance.
- Recurrent peaks may predict viral reactivation, especially in hepatitis B during pregnancy or postpartum.

Thus, serial biochemical assessment is indispensable for managing viral hepatitis in women during their reproductive years.

5. Implications for Women of Reproductive Age

Viral hepatitis poses specific reproductive health concerns:

- **Hepatitis B and C** can be vertically transmitted from mother to child, especially if viral load and liver enzyme levels are high.
- Acute infection during pregnancy increases the risk of fetal loss, preterm birth, and maternal complications.
- Chronic liver disease can impair hormonal balance, leading to menstrual irregularities and infertility.

Early detection through biochemical and serological screening enables risk stratification and preventive measures such as antiviral therapy, vaccination, and obstetric monitoring. Biochemical markers, due to their accessibility and noninvasive nature, remain essential tools for evaluating liver health before conception and during gestation.

6. Integration with Serological and Molecular Testing

While biochemical markers indicate liver injury, they must be interpreted alongside **serological** and **molecular** tests for accurate diagnosis.

- **Hepatitis B surface antigen (HBsAg)** and **anti-HCV antibodies** confirm infection status.
- **HBV DNA** and **HCV RNA** quantification assess viral replication and guide treatment decisions.
- Biochemical markers complement these findings by revealing functional impairment, thus bridging the gap between virological activity and clinical presentation.

An integrated diagnostic approach combining biochemical, serological, and molecular parameters provides the most comprehensive assessment of disease severity and prognosis.

7. Therapeutic Monitoring and Prognostic Value

Biochemical markers not only serve diagnostic purposes but also function as indicators of therapeutic efficacy and prognosis.

In antiviral treatment for hepatitis B and C:



- **ALT normalization** correlates with virological suppression.
- **Decreasing bilirubin and GGT** reflect improved hepatocellular and biliary function.
- **Stable albumin levels** suggest preserved liver synthetic capacity.

Conversely, persistent enzyme elevation despite treatment may necessitate therapy modification or indicate disease progression toward fibrosis or cirrhosis.

Monitoring biochemical markers throughout pregnancy and postpartum periods in infected women is especially vital to prevent hepatic flare-ups and ensure maternal-fetal safety.

8. Challenges in Clinical Interpretation

Despite their utility, biochemical markers have limitations:

- **Nonspecificity:** Enzyme elevation can occur in other conditions (e.g., fatty liver, drug-induced hepatotoxicity, muscle injury).
- **Physiological variations:** Pregnancy itself alters certain parameters, such as ALP and plasma proteins.
- **Delayed reflection:** Biochemical changes may lag behind histological damage or viral replication activity.

Hence, clinical context, patient history, and complementary tests are necessary for accurate interpretation.

9. Preventive and Public Health Considerations

Given the reproductive and perinatal implications, public health strategies should focus on:

- **Screening all women of childbearing age** for viral hepatitis before pregnancy.
- **Routine biochemical liver function tests (LFTs)** in antenatal care.
- **Vaccination programs** against hepatitis B and awareness campaigns on transmission routes.
- **Counseling and follow-up** for infected women to minimize complications.

Such preventive measures not only safeguard maternal health but also contribute to reducing the global burden of viral hepatitis.

10. Conclusion

Biochemical markers play a pivotal role in diagnosing, monitoring, and managing viral hepatitis among women of reproductive age. They provide critical insights into the extent of liver injury, disease progression, and therapeutic response.

Markers such as **ALT, AST, bilirubin, ALP, GGT, and albumin** are valuable indicators of hepatocellular integrity, biliary function, and synthetic capacity. When interpreted in conjunction



with serological and molecular tests, they enable early detection, effective treatment planning, and improved reproductive outcomes.

Given their accessibility, affordability, and diagnostic reliability, biochemical markers should remain central to screening and clinical management protocols for viral hepatitis, particularly in populations at risk of pregnancy-related complications.

References

- Admiraal, W., Westhoff, G., & de Bot, K. (2006). Evaluation of biochemical markers in hepatic diseases. *Journal of Hepatology Research*, 12(1), 45–52.*
- Banerjee, S., & Biswas, A. (2021). Biochemical aspects of viral hepatitis in women: Clinical implications. *International Journal of Hepatology and Gastroenterology*, 7(3), 110–118.*
- Kumar, V., & Abbas, A. (2022). *Robbins and Cotran Pathologic Basis of Disease* (11th ed.). Elsevier.*
- Mishra, P., & Rao, R. (2020). Diagnostic value of ALT and AST in viral hepatitis. *Clinical Biochemistry Journal*, 54(2), 89–97.*
- Rosen, H. R. (2018). Clinical applications of liver function tests in viral hepatitis. *Hepatology*, 68(5), 1947–1955.*
- World Health Organization (WHO). (2023). *Global hepatitis report*. WHO Press.*
- Zhou, Y., Chen, X., & Zhang, L. (2020). Biochemical and serological profiles of pregnant women with viral hepatitis. *BMC Infectious Diseases*, 20(1), 102–110.*